St. Jude Medical Furthers the Company’s Legacy of Heart Valve Excellence With US Launch of the Trifecta Surgical Valve With Glide Technology
ST. PAUL, Minn., St. Jude Medical, Inc., a
global medical device company, today announced the U.S. launch of the company’s
most advanced tissue valve — the Trifecta™ valve with Glide™ Technology (GT) —
for the treatment of patients diagnosed with unhealthy, damaged or
malfunctioning aortic heart valves. Designed with feedback from a cohort of
international physicians, the Trifecta GT tissue valve offers patients the
benefit of enhanced valve delivery to ease implantation in challenging
anatomies and during minimally invasive surgical approaches.
The launch comes as
“The
new tissue valve offers enhancements that will only make the implantation
process smoother, providing a solution to patients with even the most
challenging of cases,” said Dr.
Tissue aortic valve replacement can improve quality of life for patients suffering from valve-related heart failure symptoms and help patients with damaged or diseased native heart valves live longer lives. The original Trifecta valve provided patients a tissue valve that was proven to function in a similar way as their native aortic valve. Now, the Trifecta GT tissue valve has improved upon the original, and provides physicians a tissue valve option that is easier to implant while retaining its optimal hemodynamic performance.
Engineered to reduce wear and deterioration over time, the Trifecta GT stented tissue valve offers improved tissue-to-tissue contact when the leaflets open and close. Additionally, the valve is treated with the St. Jude Medical™ Linx™ AC Treatment, an anticalcification treatment designed to reduce tissue mineralization (hardening). The valve’s fatigue-resistant titanium stent provides a supportive frame within a patient’s heart for added durability.
“Founded
as a pioneering manufacturer of implantable bi-leaflet mechanical heart valves,
The
Trifecta GT tissue valve received
Source: St. Jude Medical
Comments